

FORM-PTO-1390
(Rev. 10-96)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

000500-182

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

Unassigned 09/319736

INTERNATIONAL APPLICATION NO.
PCT/SE97/02094 ✓INTERNATIONAL FILING DATE
12 December 1997 ✓PRIORITY DATE CLAIMED
12 December 1996 ✓

TITLE OF INVENTION

THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH IMPAIRED CELLULAR PEPTIDE PROCESSING, E.G. EXPRESSED ON RMA-S CELLS TRANSFECTED WITH A B7-1 GENE

APPLICANT(S) FOR DO/EO/US

Elisabeth WOLPERT, Klas KÄRRE, Max PETTERSSON, Johan SANDBERG ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (If known, see 37 CFR 1.53)
Unassigned 09/319736INTERNATIONAL APPLICATION NO.
PCT/SE97/02094ATTORNEY'S DOCKET NUM
000500-18217. ☒ The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$840.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482)
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00Neither international preliminary examination fee (37 CFR 1.482) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 970.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 CFR 1.492(e)).☐ 20 ☐ 30

\$

Claims

Number Filed

Number Extra

Rate

Total Claims 12 -20 =

0

X\$18.00

\$ -0-

Independent Claims 9 -3 =

6

X\$78.00

\$ 468.00

Multiple dependent claim(s) (if applicable)

+ \$260.00

\$ -0-

TOTAL OF ABOVE CALCULATIONS =

\$ 1,438.00

Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be
filed. (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 1,438.00

Processing fee of \$130.00 for furnishing the English translation later than
months from the earliest claimed priority date (37 CFR 1.492(f)).☐ 20 ☐ 30

+

\$

TOTAL NATIONAL FEE =

\$ 1,438.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 1,438.00

Amount to be:
refunded \$

charged \$

a. ☒ A check in the amount of \$ 1,438.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

SIGNATURE

Dawn M. Gardner

NAME

44,118

REGISTRATION NUMBER

THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH IMPAIRED CELLULAR PEPTIDE PROCESSING, E.G. EXPRESSED ON RMA-S CELLS TRANSFECTED WITH A B7-1 GENE

5 The present invention relates to use of substances that can induce expression of anti-
gens or epitopes associated with impaired cellular peptide processing, especially
MHC class I dependent, for preparation of pharmaceuticals, pharmaceutical com-
positions or vaccines, that stimulate specific T cell mediated immune responses
against cancer and virus infected cells. It also relates to use of antigens or epitopes
10 associated with impaired cellular peptide processing, especially MHC class I de-
pendent, or part thereof, for the same purpose. It also relates to mammalian cells that
have been manipulated to express antigens or epitopes associated with impaired
cellular peptide processing, especially MHC class I dependent, and to lymphoid cells
activated against such MHC class I dependent structures for the same purpose. Fur-
thermore, processes for such manipulation of mammalian cells and for treating hu-
man beings as well as kits for use in such manipulations are covered. The present
invention also relates to use of molecules including T-cell receptors or part thereof
directed against antigens or epitopes associated with impaired cellular peptide proc-
essing, especially MHC class I dependent, for preparation of pharmaceuticals, phar-
20 maceutical compositions or vaccines. According to the present invention, the ulti-
mate purpose of the products or processes above is the treatment, prevention and
diagnosis of cancers and virus infections.

Background of the invention

25 The immune system recognizes material foreign to the body (so called antigen) and
eliminates this material. An important part of the immune system is composed of
CD8⁺ cytotoxic T cells or T-lymphocytes (CTL), which recognize foreign and sick
cells, e.g. in virus infections or transplantation, and kill them. T cells recognize anti-
30 gen via a T cell receptor on the surfaces thereof. The T cell receptor recognizes a cell
surface molecule MHC (major histocompatibility complex) (HLA (human leucocyte

antigen) in human beings), to which a peptide is attached. MHC class I molecules are expressed on all nucleated cells, they preferentially present endogenous cellular peptides. MHC class II molecules are preferentially expressed on professional antigen presenting cells and preferentially present peptides from extracellular antigens. The recognition structure on a target cell for T-cells, e.g. a peptide bound to an MHC molecule, is called an epitope. An epitope can often be part of a larger antigen, e.g. a protein.

The production and display of MHC class I complexes occurs through a peptide processing machinery within cells, whether these are normal, virus infected or transformed to cancer cells. Cells use proteasomes to degrade cytoplasmic proteins into short peptides (1). Some of these peptides are transported from the nucleus or cytoplasm to the endoplasmic reticulum (ER) or to the Golgi apparatus by the transporter associated with antigen processing (TAP) molecule. Once inside the ER or Golgi apparatus, the peptides bind to the MHC class I protein to form a trimolecular complex. This complex is then transported to the cell surface, where it can be recognized by T lymphocyte receptors. Receptors on the surface of a particular type of T lymphocytes, known as CD8⁺ T lymphocytes, specifically recognize the MHC class I complexes that are formed by the combination of MHC class I proteins and peptides derived from a particular protein, and induce the CD8⁺ lymphocytes to kill the cells that bear those complexes. If the protein in question is of viral origin, the T-lymphocytes will thus be specific for cells infected with the relevant virus. In a viral infection many of the MHC molecules of the cell are filled with virus peptides instead of peptides from normal cellular proteins.

The intracellular chain of events leading to formation of MHC class I restricted epitopes for T-cell recognition, e.g. degradation of a native protein, peptide transport into the ER, peptide loading into MHC class I molecules, is referred to as "cellular peptide processing".

The peptides are transported into the ER by an intracellular molecular complex called TAP (2). In the absence of a functional TAP-complex, most MHC class I molecules are retained in the ER, and only a small fraction is transported to the cell surface (3-6). This has been studied in cell lines with defects in the TAP genes. The MHC class I molecules of such cells are often referred to as "empty" or "peptide receptive"; they are unstable at physiological temperature but can be stabilized by culture at low temperature or addition of exogenous MHC class I binding peptides (7-9).

TAP is considered crucial for MHC class I restricted CTL responses, because TAP-deficient cells are inefficiently recognized by conventional MHC class I restricted CTL specific for viral-, minor histocompatibility- or tumour antigens (7, 10, 11). In contrast, TAP-deficient cells can be recognized by some allo-MHC class I specific CTL (10, 12, 13). It is unclear whether such allo-specific CTL recognize MHC class I molecules per se, or MHC class I molecules loaded with TAP-independent peptides. The latter may include peptide species derived from signal sequences (14, 15), or peptides imported to the ER by other TAP-independent mechanisms.

Tumours are composed of cells, which have lost growth control, i.e. they grow without restraint and can invade normal tissue. Tumours can arise in all types of organs. Many research groups make attempts today to induce T cells to recognize and kill tumour cells. The strategy is to find proteins that are unique for the tumour and peptides from these proteins that can attach to different MHC molecules. Such peptides are then used as components in vaccines that should stimulate the immune response to the tumour. One problem is that different tumours contain different proteins, and that MHC molecules and thereby the peptides that attach to the MHC molecules, vary between individuals, as well as between tumours. Another problem is that many tumours have lost parts of the antigen processing mechanism, e.g. TAP, and, therefore, they are not discovered by conventional T cells. They lack antigenicity, and can escape from the immune response (16-19).

10 TAP-function is thus considered essential for antigenicity, and it has previously been
suggested that inhibition of TAP-function in cells should reduce or abrogate T cell
responses to the antigens expressed by the cells. For example, WO 95/15384 de-
scribes a TAP inhibitor, a protein ICP47 isolated from Herpes Simplex virus (HSV),
5 and use thereof to inhibit presentation of viral and cellular antigens associated with
MHC class I proteins to CD8⁺T lymphocytes. Several investigators emphasize
downregulation of TAP and proteasome as a way for cells to escape T-cell mediated
recognition. The present invention is based on a novel concept, namely that preven-
tion of cellular peptide processing leads to novel and unique rather than decreased
10 antigenicity of cells due to that the prevention of TAP-function leads to recognition
of novel, endogenous MHC class I dependent antigens by host T-cells that are not
recognized in the presence of a fully functional TAP-molecule. The inventors have
shown that immunization with TAP-deficient cells elicits T-cells directed against
epitopes expressed preferentially by TAP-deficient cells and that induction of such
15 T-cells can prevent cancer growth, of several tumour targets.

One application of this invention is immunotherapy of cancer, aimed at eliminating
cancer cells with insufficient capacity to process and present TAP dependent pep-
tides. Cancer is a common disease, or rather, group of diseases. Processing/TAP-
20 deficiency has recently been observed in a variety of human tumours (e g cervical
carcinoma, melanoma, breast cancer). Furthermore, the development and application
of immunotherapy protocols today will be confronted with the problem of escape
variants (with e g TAP-defects), which might even be selected by the treatment
given. Whether the epitopes turn out to be cell lineage specific or not, the principle
25 may apply to a variety of cancers, since different T-cells against different TAP-
deficient tumours may be generated. The principle applied for, may therefore be
relevant in immunotherapy treatments given to many hundreds or even thousands of
patients per year in Sweden alone.

30 Another application is the development of a HSV vaccine. HSV is a very common
virus, up to a large percentage of the Swedish population is infected, some people

have a non-symptomatic but contagious infection. Most persons with symptoms have oral ulcers, which may be very disturbing though they do not affect life-span. An uncommon severe complication is a meningitis which may be life-threatening. HSV can also cause vaginal ulcers which can cause a life-threatening infection in new-born children of infected mothers. It has been shown that HSV downregulate TAP and hence can escape "normal" MHC class I restricted CTL responses. The epitopes and method described may be a way to develop a HSV virus vaccine of which there exist none.

Summary of the invention

The following observation shows that antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, especially antigens associated with impaired TAP-function, can be used for immunization against cancer or as a virus vaccine.

One of the key observations underlying this application is that T-cells could be activated against antigens associated with impaired TAP-function. A TAP-deficient tumour cell from mouse (RMA-S) has previously been produced. This cell line is inefficient in activating responses from cytotoxic T-lymphocytes (example 1, fig 1A and B). After transfection with a stimulatory molecule B7-1 this TAP deficient tumour cell line (RMA-S.B7-1) could activate T cells to a high degree. These T cells recognize a structure independent of TAP, and, therefore, TAP-deficient tumour cells could be killed to a high degree (80% *in vitro*). The inventor has found that TAP-deficient non-transformed normal and tumour cells were capable of inducing a potent CTL response directed against MHC class I dependent epitopes expressed preferentially by TAP-deficient cells. B6 mice immunized with irradiated, B7-1 transfected TAP-deficient tumour cells, were protected from outgrowth of a subsequent transplant of TAP-deficient tumour cells, demonstrating that these novel epitopes associated with impaired TAP-function can serve as tumour rejection antigens *in vivo*.

A human TAP-deficient tumour cell is also killed by T cells elicited by TAP-deficient cells.

5 Surprisingly, several TAP-expressing murine tumour cells are also killed by CD8⁺ cells elicited by TAP-deficient cells (5/5 tested, 4 lymphomas and 1 mastocytoma) while non-transformed TAP-expressing cells (proliferating T cells, so called Con A blasts) tested from the same mouse are not killed. It was shown that the CTL recognized epitopes independent of TAP-function on tumours that have TAP-expression,
10 i.e. the tumours can have a relative but not complete impairment of TAP-function.

The inventor demonstrates that the antigens associated with impaired TAP-function can be a shared tumour antigen, which is located on several tumour cell types and hence can be used for tumour immunotherapy.

Detailed description of the invention

One object of the present invention is the use of substances that impair cellular peptide processing for MHC presentation, such as inhibitors of TAP or of the proteasome, for preparation of a pharmaceutical agent or vaccine that can stop or prevent
20 cancer growth or virus infection by stimulating immunological effectors, especially CD8⁺ cells, preferably cytotoxic cells, directed against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, in particular endogenous antigens. Another object of the present invention is the use of
25 antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, e.g. peptides or parts of MHC class I complexes, to elicit specific T-cells, preferably CD8⁺ T-cells, directed against antigens associated with impaired cellular peptide processing, for preparation of a pharmaceutical composition. Another object of the present invention is the use of T-cell receptors or parts of
30 T-cell receptors, directed against antigens or epitopes, especially MHC class I dependent, associated with impaired cellular peptide processing, for preparation of a

pharmaceutical composition. The invention also relates to the use of mixtures of such substances.

It can be tested that immunological effector cells expand and become activated against cancer or virus by culturing irradiated cells expressing antigens from cancers or viruses alone in the presence of isolated blood fractions, such as a lymphocyte fraction, and testing the effectors for recognition of target cells expressing the antigen, e.g. as is done in (11). That a substance induces expression of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, may be determined by using antibodies against MHC class I molecules and measuring MHC class I downregulation, or by recognition by effector cells directed against the antigens. The MHC class I complexes are preferably human complex HLA A, B or C. Antibodies to measure MHC class I expression can e.g. be obtained from PharMingen (San Diego, California). Downregulation of TAP-function can also be measured by peptide transporter assays, e.g. as in (33), and expression of TAP-protein can be measured with antibodies directed against TAP-molecules. Measurement of antibody binding is according to standard techniques e.g. by flow cytometry with a FACS scan analyser (Becton Dickinson).

The invention relates to all means of formation of epitopes/structures or antigens associated with impaired peptide processing, especially antigens associated with impaired TAP-function. The invention covers all substances that induce expression of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent. The substances according to the invention may therefore be any substance that inhibits the function or the expression of components that take part in the peptide processing of the cell or inhibits an active subfragment of such a substance. More specifically, the invention relates to the use of such substances in eliciting immune responses.

Examples of components that take part in the peptide processing of the cell are e.g. components involved in the translocation of peptides over the ER-membrane such as

TAP. Also, substances participating in the cytosolic processing of endogenous proteins such as the proteasome are encompassed.

The substance may be a substance that inhibits the function of TAP such as certain viral proteins e.g. TAP-inhibitors e.g. ICP47 of HSV type 1, IE 12 of HSV type 2. TAP inhibitors may be produced according to WO 95/15384.

The substance may also be one that inhibits the function of proteasome such as proteasome inhibitors such as the peptide aldehyde Z-Leu-Leu-Leu-H (Peptide Internationals Inc., Louisville, KY) or Lactacystin (Calbiochem, La Jolla, California).

Moreover, the substance may be a gene encoding an inhibitor of a substance, that takes part in the peptide processing of the cell e.g. an inhibitor of TAP or proteasome.

The substance may also be one that stops the expression of a substance, that takes part in the peptide processing of the cell e.g. TAP or the proteasome, such as a nucleotide sequence that is complementary at least in part to the RNA or DNA sequences encoding a substance, that takes part in the peptide processing of the cell e.g. antisense oligonucleotides or ribozyme destroying RNA.

Anti-sense polynucleotide sequences or analogues thereof can be used to prevent the expression of proteins in vivo or in vitro. If one adds to a cell a large number of strands of a nucleotide sequence that is complementary to the messenger RNA that is transcribed to produce a particular protein, these "anti-sense" strands will hybridize to the mRNA and limit or prevent its translation. This method could be used to limit or prevent the expression of e.g. TAP and/or proteasome. Also, antisense oligonucleotides that hybridize to DNA could be used (20, 21). Thus it is possible to treat cells with antisense TAP (22). Antisense RNA that hybridizes to mRNA can be provided either by adding RNA to cells or introducing gene sequence transcribing antisense RNA (23). Ribozymes that combine enzymatic processes with the speci-

ficity of antisense base pairing may also be used (24). These techniques are discussed in (25).

One purpose of the invention is to stimulate cells in a patient suffering from cancer or certain viruses to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent. The virus may be one that impairs peptide processing, e.g. the TAP-function such as Herpes Simplex. This could be done in vitro or in vivo.

When performed in vivo the patient is given substances that impair cellular peptide processing. Thus, compositions containing such a substance e.g. inhibitors of TAP or proteasome may be given. The patient can be vaccinated with e.g. ribozyme, antisense RNA, antisense DNA and/or antisense oligonucleotides against the expression of a substance that takes part in cellular peptide processing or a gene encoding an inhibitor of such a substance i.e. a gene encoding a substance that impairs cellular peptide processing.

DNA can be introduced directly in the cells of a living host by so called DNA immunization. This involves many different techniques e.g. intramuscular injection, intradermal injection (particle bombardment where cells in the epidermis are transfected with DNA-coated gold beads) or delivered by various vectors such as recombinant Shigella. Many other techniques are developed in different laboratories. Also RNA and oligonucleotides may be given in this way (26, 27).

Another object of the invention are cells, that have been treated to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, to be used for preparing a pharmaceutical or vaccine against cancer or virus infections.

These cells may be non-mammalian cells with impaired peptide processing e.g. cells that lack TAP and/or proteasome function and to which human MHC class I molecules have been transfected e.g. insect cells (28).

- 5 The invention preferably relates to mammalian cells and especially to autologous mammalian cells that have been treated to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent.

0 The cells may be chosen from hematopoietic cells, especially dendritic cells. Autologous cells are especially preferred.

When cancers are to be treated the cells can also be autologous cells, especially healthy cells from the affected tissue/organ.

- 5 These cells, that express MHC class I dependent antigens associated with impaired peptide processing, will then be injected into a patient in order to stimulate T cells to react on these antigens.

Another object of the invention is a process for induction of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, in mammalian cells, characterized in that:

- a) the cells are treated with agents that inhibit substances that take place in the cellular peptide processing in mammalian cells e.g. TAP-inhibiting or proteasome inhibiting agents or
- 5 b) a sequence that codes for such an inhibiting agent is introduced into the DNA of the cell or
- c) a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding a substance that takes place in the cellular peptide processing in mammalian cells e.g. TAP or proteasome is introduced into the DNA of the cell or
- d) the cells are treated with an appropriate ribozyme and

e) when non-mammalian cells are used, transfection thereof with human MHC class I molecules and

f) the cells may be irradiated with an appropriate dose with e.g. γ -irradiation from e.g. Cs^{137} .

5

The steps e) and f) represent parts of standard vaccination techniques, especially with alive cells; they are not part of the invention but may be included in the vaccination process.

10

In order to make target cells to express a foreign gene product the DNA has to be incorporated in the target cells. Plasmid DNA can be incorporated in the target cells by transfection, e.g. by electroporation, lipofection, calcium precipitation or particle resolution. Vehicles may be needed such as liposomes e.g. DOTAP (Boehringer Mannheim).

Another possibility to incorporate the foreign DNA in the target cells is the use of retroviruses, where the DNA is enveloped in a protein. In the case of retroviruses the DNA will be stably incorporated in the genome with proliferating cells. (29)

20

Mammalian cells may be cultured in a medium suitable for eucaryotic cells e.g. RPMI 1640 containing bovine serum albumin.

25

Dendritic cells can be sorted from the peripheral blood by e.g. immunomagnetic sorting to molecules such as CD34 or CD14. Magnetic beads can be obtained from Dynal. They are grown in vitro in suitable medium, e.g. IMDM (Life Technologies, Inc., Grand Island, NY) with appropriate supplements (30) and various adjuvants to improve development and immunogenicity. Examples of adjuvants are cytokines such as Granulocyte-Macrophage colony stimulating factor (GM-CSF), IL-4, Tumour Necrosis Factor alfa (TNF-alfa), stem cell factor (SCF) or Transforming Growth Factor - beta (TGF-beta), antibodies to MHC Class II or CD40 (which enhance B7 expression) or genes for costimulatory molecules.

30

5 Celis, that have been treated to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, e.g. with TAP or proteasome inhibitors, may be used for activation in vivo or in vitro of T cells against MHC class I dependent antigens associated with impaired cellular peptide processing. The in vivo procedure is described above. The in vitro procedure could be e.g. as follows:

- 10 a) cells are treated to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, as described above
b) T cells are isolated and stimulated in vitro with the cells obtained in step a and
c) activated T cells are given to the patient.

15 Stimulation of T-cells in vitro with dendritic cells is done according to current standard procedures, e.g. T-cells are sorted out from peripheral blood and cultured in the presence of dendritic cells in appropriate media and appropriate additives e.g. MEM media and IL-2 (30, 31).

20 According to one aspect of the invention lymphoid cells such as T-cells e.g. CTL, preferably CD8⁺ T lymphocytes, activated against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, are used for preparing a pharmaceutical or vaccine against cancer or virus infections.

25 Optimal conditions for human T cells and dendritic cells are e.g. as in (30, 31). T cell activation can be enhanced by treating the cells with cytokines, e.g. GM-CSF or antibodies to e.g. CD40 or MHC class II, which enhance B7 expression. Cytokines and antibodies can be obtained from ImmunoKontakt, Switzerland.

30 These cells can be tested, e.g. with T-cell clones directed against TAP-inhibited cells. Inhibition of TAP-function can be measured by peptide transporter assays, e.g. as in (32-34).

The invention also relates to a kit, for use in a process for induction of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, in cells, characterized in that it comprises an active dose of a substance that stimulates formation of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, such as an inhibitor of TAP or of proteasome or a nucleotide sequence that is at least in part complementary to the mRNA or DNA sequences encoding proteasome or TAP.

The kit may further comprise cytokines and genes for costimulatory molecules.

The invention also concerns a pharmaceutical composition or a vaccine comprising a pharmaceutically effective dose of a substance that induces antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, such as an inhibitor of TAP or of proteasome or a gene encoding a proteasome or a TAP inhibitor or a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding proteasome or TAP e.g. antisense nucleotides or ribozyme together with a pharmaceutically acceptable adjuvant.

Another object of the invention is a process for treatment, prevention and diagnosis of cancer and virus infections, characterized in that:

- a) cells taken out of the body of a human being are treated with inhibitors of cellular peptide processing, e.g. TAP-inhibitors, and are readministered to the body possibly together with a pharmaceutically acceptable adjuvant, or
- b) cells that express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, are administered to the body possibly together with a pharmaceutically acceptable adjuvant, or
- c) autologous T-cells are stimulated in vitro against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, and are administered to the body, or

d) inhibitors of cellular peptide processing for MHC class I presentation are administered to the body, such as TAP-inhibitors, together with a pharmaceutically acceptable adjuvant, or

e) antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, are administered to the body, e.g. a peptide or MHC class I complexes or a part thereof, or

f) a T-cell receptor or a part thereof directed against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, is administered to the body.

The cells are preferably autologous mammalian cells such as those mentioned herein, e.g. on page 10, line 5 to page 10, line 17.

The T-cells may be stimulated with cells that have been treated to express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, such as the cells mentioned herein, e.g. on page 9, line 25 to page 10, line 17. They may be autologous.

The amount of target cells, stimulated T-cells or inhibitors is a pharmaceutically effective amount that can be determined by the practitioner or doctor.

Adjuvants are substances that increase the effect of pharmaceutical substances, such as those mentioned on page 11, line 27-31.

Pharmaceutical compositions of the present invention contain a physiologically acceptable carrier together with at least one substance that impairs cellular peptide processing as described herein, dissolved or dispersed therein as an active ingredient.

As used herein, the term "pharmaceutically acceptable" represents that the materials are capable of administration to or upon a human without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.

The pharmaceutical composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic; inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine and the like.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.

The following observations show that antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, can be used as agents for immunization against cancer.

Summary of the observations:

- CD8⁺ T-cells can be activated against epitopes recognized preferentially expressed by TAP-deficient cells. This is shown by immunizing B6 mice with syngenic TAP-deficient tumour cells transfected with a T cell activatory molecule (TAP-deficient RMA-S tumour cells transfected with the costimulatory molecule B7-1. The cells are designated RMA-S.B7-1) and non-transformed spleen cells and dendritic cells from TAP1 ^{-/-} mice (both alleles of the TAP gene knocked out) and testing the elicited CTL on different TAP-deficient and TAP-expressing target cells (Examples 1-3).
- The recognition of epitopes is dependent of MHC class I expression. This is shown by testing elicited CTL on cells expressing different combinations of MHC class I defects (Example 2).
- The epitopes are recognized on TAP-deficient murine tumour cells and murine TAP-deficient non-transformed cells as well as on a TAP-deficient human tumour cell line (Examples 2-3).
- Surprisingly, syngenic TAP-deficient cells, both RMA-S.B7-1 tumour cells as well as spleen cells and dendritic cells from TAP1 ^{-/-} mice, elicit T cells that recognize several different syngenic TAP-expressing murine tumour cells while syngenic TAP-expressing non-transformed cells are not killed (Examples 6-8).
- The epitopes recognized on TAP-expressing tumour cells are epitopes independent of TAP-function (Example 6).
- Immunization with syngenic TAP-deficient cells can protect against tumour growth in vivo of both TAP-deficient and TAP-expressing tumour cells (Examples 5, 9).

In conclusion, the inventor demonstrates that the antigens associated with impaired TAP-function can be a shared tumour antigen, which is located on several tumour cell types and hence can be used for tumour immunotherapy.

5

10

15

20

25

30

In the experiments B6 mice are immunized with syngenic TAP-deficient cells e.g. cells from TAP1^{-/-} mice where the TAP1 gene has been deleted by genetic manipulation. In a living human being this is not possible yet. However, cells treated with antisense oligonucleotides against TAP have the same cellular phenotype as cells where TAP-function has been abrogated by structural genetic changes as in the mutant cell line RMA-S or cells from mice where TAP has been deleted by genetic manipulation (TAP knock-out mice) (22). This phenotype is characterized e.g. by decreased cell surface expression of MHC class I molecules, which can be upregulated by incubation at 26°C, also by an enhanced stimulatory capacity to externally added antigens. The key difference between the invention and such studies is that the inventors have found that TAP-inhibition adds novel endogenous MHC class I dependent antigens for CD8⁺ T cell recognition. It is further shown that these are recognized on a variety of different tumour cells. Since the human cell line T2K^b is recognized by the elicited CTL, the epitopes associated with impaired TAP-function can also be recognized on human cells. In the human, autologous or MHC matched cells can be treated with TAP-inhibitors of different kinds; these cells can be used to elicit CTL against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent. According to the data presented these CTL may be used in immunotherapy of both TAP-deficient and TAP-expressing tumours. From the literature it is also known that several viruses can inhibit antigen presentation and hence escape conventional CTL recognition. For example, Herpes Simplex inhibits TAP-function (33, 34). Therefore CTL elicited by TAP-inhibited cells may also be used as a therapeutical agent in viral infections where TAP-function is inhibited as above. The presentation of MHC class I molecules and TAP-dependent peptides at the cell surface is a complex process depending on many factors, of which translocation of peptides over the ER-membrane by TAP-molecules is

one. Another crucial step is cytosolic processing of endogenous proteins by the proteasome. Cells that lack components of the proteasome have a similar phenotype to TAP-deficient cells, i.e. deficient generation of antigenic peptide. Proteasome inhibitors block MHC class I restricted antigen presentation and assembly of MHC class I molecules, the assembly can be reconstituted by exogenously added peptides (1, 35-37). It is likely that the epitopes associated with impaired TAP-function will be exposed also upon inhibition of the proteasome and could with a more general term be named MHC class I dependent epitopes associated with impaired cellular peptide processing. Therefore the invention also relates to the elicitation of T cells with proteasome inhibitors. It is also easy to envisage that other yet undefined factors are necessary for formation of the MHC/TAP-dependent-peptide complex and that inhibition of those factors will result in a similar phenotype exposing epitopes associated with impaired TAP-function.

This underlying discovery reveals the existence of MHC class I dependent CTL epitopes that are recognized preferentially in the absence of a functional TAP complex. B6 mice immunized with B7-1 transfected TAP-deficient RMA-S tumour cells or spleen cells from TAP1 $-/-$ mice, generated a potent CTL response against both RMA-S tumour cells and TAP1 $-/-$ Con A blasts targets. In contrast, TAP-expressing RMA-S.TAP2 tumour cells and B6 Con A blasts were largely resistant to lysis by these CTL. RMA-S.B7-1 immunized mice were protected from outgrowth of RMA-S tumour transplants, indicating that these epitopes associated with impaired TAP-function can serve as tumour rejection antigens in vivo. Surprisingly, several TAP-expressing tumours were also sensitive to the elicited CTL while non-transformed cells were resistant. It was shown that the CTL recognized epitopes independent of TAP-function on tumours that still have TAP-expression, i.e. they can have a relative but not complete impairment of TAP-function. The difference in sensitivity between RMA and RMA-S.TAP2 which are both TAP-expressing is probably due to that RMA-S.TAP2 is a transfectant with TAP and hence can overexpress TAP compared to the levels in the original tumour RMA.

In the experiments described B6 mice have been immunized with syngenic TAP-deficient cells. A human correlate is to elicit CTL with TAP-deficient cells, e.g. autologous cells to which TAP-inhibitors have been introduced. According to the data presented these CTL may be used in immunotherapy of both TAP-deficient and TAP-expressing tumours. These CTL may also be used as therapeutical agent in viral infections where TAP-function is inhibited (33, 34). This study is done with several different tumour cells of lymphoid origin. Also a non-lymphoid cell line, the H-2Kb transfected mastocytoma P815 is killed by the elicited CTL.

The agents according to the invention may be used against tumours, preferentially that have lost expression of TAP, but also towards TAP-expressing tumours. The agents may also be used against certain virus infections where TAP-function is inhibited by viral proteins, e.g. in Herpes Simplex virus infected cells.

Brief description of the drawings:

Figure legends

Figure 1. Immunization of B6 mice with RMA-S.B7-1 cells elicits CD8⁺ CTL that recognize non-transfected RMA-S cells. (A and B) B6 mice were immunized in vivo and splenocytes were restimulated in vitro with RMA-S tumour cells (O) or RMA-S cells transfected with B7-1 (◆) and tested for cytotoxicity against RMA-S target cells. Two experiments are shown, panel A is representative of 4/6 experiments, panel B is representative of the remaining experiments. (C) CTL generated as above were depleted with anti-CD8 antibodies and complement (▲) or anti-CD4 antibodies and complement (Δ) and tested for cytotoxicity against RMA-S target cells. One representative experiment out of three is shown.

Figure 2. Recognition of epitopes by RMA-S.B7-1 elicited CTL requires the absence of TAP-function and the presence of MHC class I molecules in the target cell. B6 mice were immunized in vivo and splenocytes were restimulated in vitro with

RMA-S.B7-1 cells and tested for cytotoxicity against (A) RMA-S (○) and RMA-S.TAP-2 (●), (B) Con A blasts from B6 (□), TAP1 ^{-/-} (■), β_2m ^{-/-} (△), and TAP1/ β_2m ^{-/-} mice (▲) and (C) T2 (▽) and T2K^b (▼) cells. One representative experiment out of three is shown.

Figure 3. Immunization with TAP1 ^{-/-} splenocytes elicits CTL that recognize TAP1 ^{-/-} Con A blasts and RMA-S tumour cells. B6 mice were immunized in vivo and splenocytes were restimulated in vitro with splenocytes from TAP1 ^{-/-} mice and tested for cytotoxicity against RMA-S (○), B6 Con A blasts (□) and TAP1 ^{-/-} Con A blasts (■). One representative experiment out of four is shown.

Figure 4. Immunization of B6 mice with RMA-S.B7-1 cells protects from out-growth of RMA-S tumour cells. B6 mice were given 10⁶ live RMA-S tumour cells after immunization with PBS (), RMA-S (○) or RMA-S.B7-1 (◆). The figure represents the accumulated data of four separate experiments (three for RMA-S.B7-1) with 4-6 mice/immunization group in each experiment.

Figure 5. The TAP-expressing tumour RMA expresses epitopes independent of TAP-function. B6 mice were immunized in vivo and splenocytes were restimulated in vitro with RMA-S.B7-1 tumour cells and tested for cytotoxicity against (A) RMA-S (□), RMA (), RMA-S.TAP2 (○) or B6 Con A blasts (△), (B) RMA to which cold B6 Con A blasts (□) or TAP1 ^{-/-} Con A blasts () in designated ratios were added.

Figure 6. Several TAP-expressing tumour cell lines are killed by CTL elicited by RMA-S.B7-1, while non-transformed TAP-expressing cells are resistant. B6 mice were immunized in vivo and splenocytes were restimulated in vitro with RMA-S.B7-1 tumour cells and tested for cytotoxicity against RMA-S (□), EL-4 (), ALC (○), C4425- (△), P815 (▽), B6 Con A blasts (■) and TAP1 ^{-/-} Con A blasts (◆). One representative experiment out of three is shown.

Figure 7. Immunization with TAP1 $-/-$ dendritic cells elicits CTL that recognize several TAP-expressing tumour cells. B6 mice were immunized in vivo with dendritic cells from TAP1 $-/-$ mice and splenocytes were restimulated in vitro with splenocytes from TAP1 $-/-$ mice and tested for cytotoxicity against RMA-S (\square), EL-4 (\circ), ALC (\circ), RMA (Δ), P815K^b (\blacktriangle), 26E1Nmyc (\blacktriangledown) and B6 Con A blasts (\blacksquare). One experiment of two is shown.

Figure 8. Immunization of B6 mice with RMA-S.B7-1 cells protects from out-growth of several TAP-expressing tumour cells. B6 mice were immunized with PBS (\circ) or RMA-S.B7-1 (\square), or CD8 $-/-$ mice were immunized with PBS (Δ) or RMA-S.B7-1 cells (\circ) and given in (A) 10^5 RMA tumour cells, (B) 10^2 EL-4 tumour cells (C) 10^3 ALC tumour cells. The figure represents one experiments with 4-6 mice/immunization group.

The invention will now be described by reference to some non limiting examples

All technical and scientific terms used herein are, unless otherwise defined, intended to have the same meaning as commonly understood by one of ordinary skill in the art. Techniques employed herein are those that are known to one of ordinary skill in the art unless stated otherwise. Publications mentioned herein are incorporated by reference.

Materials and Methods

Mice. All mice were bred and maintained at the Microbiology and Tumour Biology Center, Karolinska Institute. The generation and characterization of TAP1 $-/-$, β_2 -microglobulin (β_2m) $-/-$ and TAP1/ β_2m $-/-$ mice has been described (38-40). The TAP1 $-/-$ and β_2m $-/-$ mice used in the present study have been backcrossed to B6

(C57BL/6) at least six times. Animal care was in accordance with institutional guidelines.

Cell lines. T2K^b is a H-2K^b (mouse MHC allele (type)) transfected subline of the TAP1/2 deficient mutant human cell line T2 (41). All cell lines were grown in RPMI 1640 medium (Life Technologies, Gaithersburg, MD) supplemented with penicillin-streptomycin and 5% FCS (Fetal Calf serum) at 37°C and 5% CO₂.

Antibodies. B7-1 (RMA-S.B7-1) expression was assessed either with the CTLA-4Ig fusion protein (42), a kind gift from Dr P. Lane, Basel Institute for Immunology, Basel, Switzerland, and a FITC (Fluorescein isothiocyanate)-conjugated anti-human IgG antibody (Dako, Glostrup, Denmark), or with a biotinylated anti-B7-1 monoclonal antibody 16-10A1 (PharMingen, San Diego, CA) and NEUTRALITE avidin-FITC (Southern Biotechnology Associates Inc., Birmingham, AL).

Cold target competition assay. For the cold target competition assay cold (unlabeled) Con A blasts were incubated at different concentrations with a constant number of effector cells and 5×10^3 ⁵¹Cr-labeled target cells.

Immunization with bone marrow derived dendritic cells. Bone marrow derived derived dendritic cells were obtained from TAP1^{-/-} mice using the protocol of Inaba and colleagues (43) with the following alterations. Bone marrow cells were cultured in Dulbecco's modified Eagles Medium containing 10 % supernatant from the GM-CSF (Granulocyte Macrophage Colony Stimulating Factor secreting cell line X63 (a kind gift from Dr C.Watts, Univ Dundee, Dundee, UK) and 20 % FCS. The culture media was replaced every third day, and the cells were replated on day 7. On the eight day, the non-adherent cells were used for in vivo immunization. 10⁵ cells were given intraperitoneally, splenocytes were restimulated 10 days after in vivo immunization.

Examples

A. CD8⁺ T cells can be elicited to MHC class I dependent epitopes associated with impaired TAP-function. Immunization with a TAP-deficient cell can protect against tumour growth in vivo.

Example 1

RMA-S cells transfected with B7-1 (CD80) elicit CTL that recognize non-transfected RMA-S cells.

B6 mice were immunized with three weekly s.c. injections of 10^7 irradiated (100 Gray (Gy)) tumour cells. Tumours used were serially passaged as ascites cell lines in 4 Gy irradiated mice. The tumour cells were TAP-2 deficient ones, called RMA-S cells (derived from the Rauscher leukaemia virus-induced mouse T-cell lymphoma RBL-5 of B6 origin (44)), which were transfected with B7-1, i.e. 2×10^6 RMA-S cells were incubated with 10 μ l LIPOFECTAMINE (Life Technologies, Gaithersburg, MD) and 1 μ g of the murine B7-1 gene cloned in a pSRIneo plasmid (45), a gift from Bristol Meyers Inc, Seattle, to Prof Klaus Kärre. Transfected cells were selected on GENETICIN (Life Technologies, Gaithersburg, MD) at a concentration of 1 mg/ml. The 1 % most positive fraction of the B7-1 expressing RMA-S cells were sorted on a FACS VANTAGE cell sorter (Becton Dickinson, Mountain View, CA) and designated RMA-S.B7-1.

This transfection resulted in strong and reproducible lysis of non-transfected RMA-S targets (Fig. 1 A and B). The lysis could be abrogated by pre-treatment of effectors with anti-CD8 antibodies (CD8 is a marker of the cell surface of CTL) and complement (Fig. 1 C). The complement-mediated depletion of effector populations was conducted as follows: 20×10^6 effector cells were incubated in 200 μ g of anti-CD8 antibody (a mixture of 169.4 and 156.7.7 in 1 ml PBS, or 200 μ g of anti-CD4 antibody (YTS191) in 1 ml PBS for 60 min at 4°C. All antibodies were generously provided by Dr H. Waldman, University of Cambridge, Cambridge, UK. The cells were

washed once and incubated with rabbit complement (Pel-Freeze Biologicals, Brown Deer, WI) diluted 1:8, for 75 min in 37°C.

This demonstrates that it is possible to generate CTL against syngenic TAP-deficient cells. Control cell lines. YAC-1 (a Moloney virus induced T cell lymphoma of A/Sn background) and P815 (a Methylcholantrene induced mastocytoma of DBA/2 background), as well as Concanavalin A (Con A) blasts from BALB/c mice were resistant to lysis by these CTL (data not shown). The generation of Con A-activated T-cell blasts was as follows: Spleen cells were incubated for 48 h at 2×10^6 cells/ml in α -MEM medium (Life Technologies, Gaithersburg, MD) supplemented with penicillin-streptomycin, 10 % FCS, 10 mM HEPES (Life Technologies, Gaithersburg, MD), 3×10^{-5} M 2-ME (2-Mercaptoethanol) (Sigma, St. Louis, MO) and 3 μ g/ml of Con A (Sigma, St. Louis, MO). Before use as targets in a standard 4 h ^{51}Cr cytotoxicity assay, dead cells were removed by centrifugation on a LYMPIOPREP gradient (Nycomed, Oslo, Norway).

TAP-2 deficient RMA-S tumour cells were inefficient in eliciting cytotoxic responses in B6 mice (Fig. 1 A and B).

Example 2

CTL recognition requires the presence of MHC class I molecules and the absence of TAP in the target cell.

A TAP-2 transfectant of RMA-S (RMA-S.TAP2 cells, also referred to as RMA-S II 5.9 cells, were derived by transfection of RMA-S with the murine TAP-2 gene (46)) was virtually resistant to lysis by RMA-S.B7-1 elicited CTL (Fig. 2 A) as in Example 1. This indicated that the epitopes were recognized preferentially in cells devoid of TAP expression. In line with this, Con A blasts from TAP1 $-/-$ mice were highly sensitive to lysis, whereas Con A blasts from B6 mice were resistant to lysis. Con A blasts from TAP1/ $\beta_2\text{m}$ $-/-$ (double mutant) mice were resistant to lysis, suggesting an MHC class I dependence in the CTL recognition of epitopes (Fig. 2 B).

Indeed, the human TAP-deficient cell line T2 transfected with H-2K^b was sensitive to lysis by RMA-S.B7-1 elicited CTL, while non-transfected T2 cells were resistant (Fig. 2 C). Taken together, these results indicate that at least part of the response elicited by RMA-S.B7-1 is MHC class I specific or restricted and directed against epitopes expressed preferentially, if not exclusively, by TAP-deficient cells. At least some of the epitopes could be recognized on both non-transformed and transformed lymphoid cells, and on cells of both human and murine origin. These epitopes will be referred to as epitopes associated with impaired TAP-function.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199

Example 3

TAP1 -/- splenocytes elicit CTL that recognize TAP1 -/- Con A blasts and RMA-S tumour cells.

5

As shown above, CTL elicited by RMA-S.B7-1 killed TAP1 -/- Con A blasts. Accordingly, immunization of B6 mice with splenocytes from TAP1 -/- mice yielded cytotoxic cells that efficiently lysed TAP1 -/- Con A blasts and RMA-S tumour cells while B6 Con A blasts and RMA-S.TAP2 were killed at markedly reduced levels (Fig. 3; data not shown). The killing of the TAP-deficient cells was also seen with effectors from mice depleted of NK (natural killer) cells (data not shown). B6 mice were immunized with two weekly s.c. injections of 50×10^6 irradiated (20 Gy) spleen cells.

10
15
20
25

Example 4

Generation of primary CTL by the epitopes associated with impaired TAP-function.

Stimulation in vitro, without prior in vivo immunization, of B6 spleen cells with RMA-S.B7-1 and TAP1 -/- spleen cells was conducted as follows: Single cell suspensions of spleens from immunized or non-immunized mice were prepared. 20×10^6 effector cells were incubated with 2×10^6 irradiated tumour cells or 20×10^6 irradiated spleen cells. Cultures were kept in 10 ml of RPMI 1640 medium supplemented with penicillin-streptomycin, 10 % FCS, 3×10^{-5} M 2-ME, 1 mM sodium pyruvate, 0,1 mM non-essential amino acids and 2 mM L-glutamine at 37° C and 5 % CO₂ for five days.

20

25

This stimulation reproducibly resulted in cytotoxic responses against RMA-S and TAP1 -/- Con A blasts targets, while RMA-S.TAP2 and B6 Con A blasts were considerably less sensitive. The in vitro cytotoxicity assay was conducted as follows: Target cells were labelled with ^{51}Cr and resuspended in cell culture medium. 5×10^3

30

target cells were added to each well followed by addition of effector cells. The cells were incubated for 4 h at 37°C and supernatants were harvested. Radioactivity was measured in a Pharmacia-LKB γ -counter, and specific lysis was calculated [(CPM (counts per minute) released with effector cells-CPM released without effector cells) / (CPM released by detergent-CPM released without effector cells)] x 100. Results with more than 20 % spontaneous lysis were discarded.

Stimulation in vitro with non-transfected RMA-S cells yielded in some experiments lower levels of lysis (Table I; data not shown). The killing of RMA-S and TAP1 -/- Con A blast targets was abrogated by pre-treatment of effectors with anti-CD8 antibody and complement (data not shown).

Example 5

Immunization of B6 mice with RMA-S.B7-1 protects against RMA-S tumour growth.

To address whether it was possible to elicit a protective immune response against a TAP-deficient tumour cell line, we immunized B6 mice with RMA-S cells, RMA-S.B7-1 cells or PBS (phosphate buffered saline). After three weekly immunizations, mice were challenged with 10^6 live RMA-S tumour cells s.c., a dose previously found to overcome the NK mediated rejection of RMA-S (41). The in vivo tumour growth was as follows: B6 mice were immunized as described. One week after the last immunization, mice were given 10^6 live tumour cells s.c. and growth was followed weekly by palpation. For each mouse, the experiment was terminated when the tumour reached a diameter of 20 mm.

Eighty nine percent of the mice (17/19 mice) immunized with PBS developed progressively growing tumours within three weeks after challenge. In contrast, only eight percent (1/13) of the mice immunized with RMA-S.B7-1 developed tumours. Mice immunized with RMA-S were partially protected: Fifty five percent of the mice (10/18 mice) developed progressively growing tumours (Fig. 4).

The RMA-S.B7-1 mediated protection from tumour growth was also seen in NK 1.1 depleted mice (data not shown).

B. Epitopes associated with impaired TAP-function is a shared tumour antigen found on several TAP-expressing tumours but not on non-transformed cells. Immunization with a TAP-deficient cell protects in vivo against tumour growth of TAP-expressing tumour cells.

Example 6

The TAP-expressing tumour cell RMA is recognized by CTL directed to epitopes associated with impaired TAP-function.

Surprisingly, CTL elicited by RMA-S.B7-1 reproducibly killed the TAP-expressing parental tumour cell of RMA-S, RMA. The lysis levels were markedly higher than with the TAP-transfected tumour cell line RMA-S.TAP2, but still below the levels of lysis of the TAP-deficient cell RMA-S (Fig 5A). As described above, no killing was observed of TAP-expressing B6 Con A blasts. In cold target inhibition experiments with Con A blasts from B6 and TAP-/- mice, the latter were more efficient in inhibiting lysis of RMA by CTL elicited by RMA-S.B7-1 (Fig 5B), demonstrating that at least part of the killing of RMA by these CTL was dependent on recognition of epitopes independent of TAP-function. Control experiments where hot and cold targets were incubated without effectors did not result in any lysis by either cold target (data not shown).

Example 7

Several TAP-expressing tumour cell lines are killed by CTL elicited by RMA-S.B7-1 while non-transformed TAP-expressing cells are resistant.

A possible explanation to the observed killing of RMA is that some tumour cells may have a relative deficiency in TAP-function, i.e. they express suboptimal levels of TAP-proteins. To investigate whether epitopes associated with impaired TAP-function could be a shared antigen we tested other H-2^b expressing tumour cell lines transformed by different agents, for killing by RMA-S.B7-1 elicited CTL. Indeed, all tumour cells tested, the carcinogen induced (9,10-dimethyl-1,2-benzanthracene) EL-4 (American Type Culture Condition, Rockville, MD), the Radiation Leukaemia virus induced ALC (generously provided by Dr Wen Tao, Karolinska Institute, Sweden) and 26E-1Nmyc tumour cells (a gift from Dr Santiago Silva, Karolinska Institute, Sweden) were killed by RMA-S.B7-1 elicited CTL. 26E1Nmyc is a spontaneous lymphoma from mice transgenic for EBNA-1 and N-myc (derived by crossing EBNA-1 and N-myc transgenic mice (47, 48)). A β_2m -negative variant of EL-4, as well as P815 tumour cells (a mastocytoma of a H-2^d origine obtained from American Type Culture Condition, Rockville, MD) were not killed by RMA-S.B7-1 elicited CTL (Fig 6). Of the cells described above, only H-2^d positive P815 and 26E-1Nmyc cells were killed by B6 CTL elicited by Balb/c splenocytes (data not shown) showing that the tumour cells were not generally sensitive for all CTL tested.

Example 8

TAP-deficient nontransformed cells elicit CTL that recognize several TAP-expressing tumour cell lines but not TAP-expressing non-transformed cells.

CTL from B6 mice immunized with splenocytes or cultured dendritic cells from TAP1 -/- mice also killed RMA, ALC, 26E-1Nmyc, EL-4 (to lower levels), P815 cells transfected with H-2K^b and TAP1 -/- Con A blasts. B6 Con A blasts were not killed by these CTL (Fig 7). This strengthens the notion that TAP-expressing tumour cells but not non-transformed cells express epitopes associated with impaired TAP-function. The lysis levels were lower than those observed with RMA-S.B7-1 which is probably due to the high levels of B7 expression on RMA-S.B7-1.

Example 9

Immunization with RMA-S.B7-1 protects from tumour growth of several TAP-expressing tumours.

B6 mice were immunized with RMA-S.B7-1 or non-immunized. One week after the last immunization mice were given 10^5 RMA tumour cells or 10^2 EL-4 tumour cells or 10^3 ALC tumour cells. In the immunized groups only 20 % of mice developed tumours while all mice in the non-immunized groups developed progressively growing tumours. For RMA and EL-4 the protection observed in the immunized mice was not seen in mice deficient of CD8, demonstrating that this protection was mediated by CD8⁺ CTL (Fig 8 A-C).

References

1. Groettrup, M., A. Soza, U. Kuckelkorn and P.-M. Kloetzel. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. *Immunol. Today*. 9:429-435.
2. Heemels, M.T, and H. Ploegh. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. *Annu. Rev. Biochem.* 64:463-491.
3. Powis, S.J., A.R. Townsend, E.V. Deverson, J. Bastin, G.W. Butcher, and J.C. Howard. 1991. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. *Nature*. 354:528-531.
4. Spies, T, and R. DeMars. 1991. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. *Nature*. 351:323-324.
5. Degen, E., M.F. Cohen-Doyle, and D.B. Williams. 1992. Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both β_2 -microglobulin and peptide. *J. Exp. Med.* 175:1653-1661.
6. Suh, W.K., E.K. Mitchell, Y. Yang, P.A. Peterson, G.L. Waneck, and D.B. Williams. 1996. MHC class I molecules form ternary complexes with calnexin and tap

and undergo peptide-regulated interaction with TAP via their extracellular domains.

J. Exp. Med. 184:337-348.

7. Townsend, A., C. Öhlén, J. Bastin, H.G. Ljunggren, L. Foster, and K. Kärre. 1989. Association of class I major histocompatibility heavy and light chains induced by viral peptides. *Nature*. 340:443-448.

8. Ljunggren, H.G., N.J. Stam, C. Öhlén, J.J. Neefjes, P. Höglund, M.T. Heemels, J. Bastin, T.N. Schumacher, A. Townsend, and K. Kärre. 1990. Empty MIIC class I molecules come out in the cold. *Nature*. 346:476-480.

9. Day, P.M., F. Esquivel, J. Lukszo, J.R. Bennink, and J.W. Yewdell. 1995. Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. *Immunity*. 2:137-147.

10. Öhlén, C., J. Bastin, H.G. Ljunggren, L. Foster, E. Wolpert, G. Klein, A.R. Townsend, and K. Kärre. 1990. Resistance to H-2-restricted but not to allo-H2-specific graft and cytotoxic T lymphocyte responses in lymphoma mutant. *J. Immunol.* 145:52-58.

11. Franksson, L., M. Petersson, R. Kiessling, and K. Kärre. 1993. Immunization against tumour and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. *Eur. J. Immunol.* 23:2606-2613.

12. Aosai, F., C. Öhlén, H.G. Ljunggren, P. Höglund, L. Franksson, H. Ploegh, A. Townsend, K. Kärre, and H.J. Stauss. 1991. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. *Eur. J. Immunol.* 21:2767-2774.

13. Rötzschke, O., K. Falk, S. Faath, and H.G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. *J. Exp. Med.* 174:1059-1071.

14. Wei, M.L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. *Nature*. 356:443-446.

15. Henderson, R.A., A.L. Cox, K. Sakaguchi, E. Appella, J. Shabanowitz, D.F. Hunt, and V.H. Engelhard. 1993. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. *Proc. Natl. Acad. Sci. U. S. A.* 90:10275-10279.

16. Restifo, N.P., F. Esquivel, Y. Kawakami, J.W. Yewdell, J.J. Mule, S.A. Rosenberg, and J.R. Bennink. 1993. Identification of human cancers deficient in antigen processing. *J. Exp. Med.* 177:265-272.
17. Cromme, F.V., J. Airey, M.T. Heemels, H.L. Ploegh, P.J. Keating, P.L. Stern, C.J. Meijer, and J.M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. *J. Exp. Med.* 179:335-340.
18. Seliger, B., A. Hohne, A. Knuth, H. Bernhard, T. Meyer, R. Tampe, F. Momberg, and C. Huber. 1996. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. *Cancer Res.* 56:1756-1760.
19. Garrido, F., T. Cabrera, A. Concha, S. Glew, F. Ruiz-Cabello, and P.L. Stern. 1993. Natural history of HLA expression during tumour development. *Immunol. Today.* 14:491-499.
20. Crooke, S.T., Bennett, C.F. 1996. Progress in antisense oligonucleotide therapeutics. *Annual Review of Pharmacology & Toxicology* 36:107-129.
21. Zon, G. 1995. Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible mechanisms of toxicity. *Toxicology Letters*, Dec. 82-83:419-424.
22. Nair, S.K., D. Snyder, and E. Gilboa. 1996. Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. *J. Immunol.* 156:1772-1780.
23. Sharma H.W., Narayanan, R. 1996. The NF-kappaB transcription factor in oncogenesis. *Anticancer Research*, Mar-Apr, 16(2):589-596.
24. Ohkawa, J., Koguma, T., Kohda, T., Taira, K. 1995. Ribozymes: from mechanistic studies to applications in vivo. *Journal of Biochemistry*, Aug, 118(2):251-258.
25. Putnam, D.A. 1996. Antisense strategies and therapeutic applications. *American Journal of Health-System Pharmacy*, Jan, 15;53(2):151-160.
26. Ulmer J.B., J.C. Sadoff and M.A. Liu. 1996. DNA vaccines. *Current Opinion in Immunology.* 8:531-536.

27. Tascon, RE., Colston MJ., Ragno, S., Stavropoulos, E., Gregory, D., Lowrie, DB. 1996. Vaccination against tuberculosis by DNA injection. *Nature Medicine*, Aug, 2(8):888-892.
28. Uebel S., T.H. Meyer, W Kraas, S. Kienle, G. Jung, K.H. Wiesmuller, and R. Tampe. 1995. Requirements for peptide binding to the human transporter associated with antigen processing revealed by peptide scans and complex libraries. *J. Biological Chemistry* 270 (31):18512-18516.
29. WO 96/33272.
30. Strobl H., E. Riedl, C. Scheinecker, C. Bello-Fernandez, W.F. Pickl, K. Rappersberger, O. Majdic and W. Knapp. 1996. TGF-beta1 promotes in vitro development of dendritic cells from CD34⁺ hemopoietic progenitors. *J. Immunology*. 157(4):1499-507.
31. Kiertcher S.M., and Roth M.D. 1996. Human CD14⁺ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. *Journal of Leukocyte Biology* 59(2):208-218.
32. Obst, R., Armandola, EA., Nijenhuis, M., Momburg, F., Hammerling, GJ. 1995. TAP polymorphism does not influence transport of peptide variants in mice and humans. *European Journal of Immunology*. Aug. 25(8):2170-2176.
33. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. *Nature*. 375:411-415.
34. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P.M. van Endert, R. Tampe, P.A. Peterson, and Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. *Nature*. 375:415-418.
35. Rock, K.L., C. Graham, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang and A.L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell*. 78:761-771.
36. Harding C.V., J. France, R. Song, J.M, Farah, S. Chatterjee, M. Iqbal, and R. Siman. 1995. Novel dipeptide aldehyds are proteasome inhibitors and block the MHC class I antigen processing pathway. *J. Immunol*. 155:1767-1775.

37. Fehling H.J., W. Swat, C. Laplace, R. Kuhn, K. Rajewsky, U. Muller, and H. von Boehmer. 1992. MHC class I expression in mice lacking the proteasome subunit LMP-7. *Science* 265:1234.
38. Koller, B.H., P. Marrack, J.W. Kappler, and O. Smithies. 1990. Normal development of mice deficient in β_2 -microglobulin, MHC class I proteins, and CD8⁺ T cells. *Science*. 248:1227-1230.
39. Van Kaer, L., P.G. Ashton-Rickardt, H.L. Ploegh, and S. Tonegawa. 1992. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4⁺8⁺ T cells. *Cell*. 71:1205-1214.
40. Ljunggren, H.G., L. Van Kaer, M.S. Sabatine, H. Auchincloss Jr, S. Tonegawa, and H.L. Ploegh. 1995. MHC class I expression and CD8⁺ T cell development in TAP1/ β_2 -microglobulin double mutant mice. *Int. Immunol.* 7:975-984.
41. Cerundolo, V., J. Alexander, K. Anderson, C. Lamb, P. Cresswell, A. McMichael, F. Gotch, and A. Townsend. 1990. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. *Nature*. 345:449-452.
42. Lane, P., W. Gerhard, S. Hubele, A. Lanzavecchia, and F. McConnell. 1993. Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human $\gamma 1$. *Immunology*. 80:56-61.
43. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Murumatsu S. and Steinman R.M. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 176 (6):1693-1702.
44. Karre, K., H.G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature*. 319:675-678.
45. Takebe, Y., Seiki, M., Fujisawa, J-I., Hoy, P., Yokota, K., Arai, K-I., Yoshida, M. and Arai, N. 1988. Sr α Promotor: an efficient and versatile Mammalian cDNA expression system composed of the simina virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Molecular and Cellular Biology*, 466-472.

46. Zhou, X., R. Glas, F. Momburg, G.J. Hammerling, M. Jondal, and H.G. Ljunggren. 1993. TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. *Eur. J. Immunol.* 23:1796-1801.
47. Wilson, J.B., Bell, J.L., Levine, A.J. 1996. Expression of Epstein-Barr virus nuclear antigen 1 induces B-cell neoplasia in transgenic mice. *EMBO Journal*, Jun 17, 15(12):3117-3126.
48. Dildrop R.M.A.A., Zimmerman, K. Hsu, E., Tesfaye, A., DePinho, R., Alt, F.W. 1989. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. *EMBO Journal*. Apr. 8 (4):1121-1128.

Table 1. Generation of primary CTL by Epitopes Associated with impaired TAP-function*

Effector Cells	Effector: Target ratio	Target Cells			
		TAPI -/+	$\beta_2m^{-/-}$	B6	RMA-S TAP2
B6 anti-TAPI -/-	60:1	77 [§]	22	26	20
	20:1	58	4	24	12
	7:1	41	2	18	8
B6 anti-RMA-S.B7-1	60:1	48	14	1	21
	20:1	25	10	0	16
	7:1	14	3	0	8
B6 anti-RMA-S	60:1	0	4	0	4
	20:1	ND	ND	ND	ND
	7:1	ND	ND	ND	ND

* The table shows one representative experiment out of three.

Con A blasts from TAPI -/-, $\beta_2m^{-/-}$ and B6 mice[§] Percent specific lysis^{||} Not done

Claims

1. Use of substances that impair cellular peptide processing for MHC presentation, such as inhibitors of TAP (transporters associated with antigen processing) or of the proteasome, for preparation of a pharmaceutical agent or vaccine that can stop or prevent cancer growth or virus infection by stimulating immunological effectors, especially CD8⁺ cells, preferably cytotoxic cells, directed against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent.
2. Use of substances according to claim 1, **characterized** in that the substances inhibit the function and/or the expression of TAP such as TAP-inhibitors e.g. ICP47 of HSV type 1, IE 12 of HSV type 2 or a gene encoding a TAP inhibitor or a nucleotide sequence that is complementary at least in part to the RNA or DNA sequences encoding TAP e.g. antisense oligonucleotides or ribozyme destroying RNA.
3. Use of substances according to claim 1, **characterized** in that the substances inhibit the function and/or the expression of proteasome such as proteasome inhibitors e.g. a peptide aldehyde Z-Leu-Leu-H or Lactacystin, or a gene encoding a proteasome inhibitor or a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding proteasome e.g. antisense oligonucleotides or ribozyme destroying RNA.
4. Use of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, e.g. peptides or parts of MHC class I molecules, to elicit specific T-cells, preferably CD8⁺ T-cells, directed against antigens or epitopes associated with impaired cellular peptide processing, for preparation of a pharmaceutical composition.

5. Use of molecules including T-cell receptors or parts of T-cell receptors, directed against MHC class I dependent antigens or epitopes associated with impaired cellular peptide processing, for preparation of a pharmaceutical composition.

5 6. Cells, that express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, chosen from mammalian cells or non-mammalian cells, e.g. cells that lack TAP and/or proteasome function and to which human MHC class I molecules could be transfected, to be used for preparing a pharmaceutical or vaccine against cancer or virus infections, by stimulating immunological effectors, especially CD8⁺ cells, preferably cytotoxic cells, directed against
10 antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent.

15 7. Cells according to claim 6, **characterized** in that they are mammalian cells such as hematopoietic cells, e.g. dendritic cells, or other autologous cells, especially cells from the tissue of the origin of a cancer, or non-mammalian cells, such as insect cells.

20 8. Lymphoid cells such as T-cells e.g. CTL, preferably CD8⁺ T lymphocytes activated against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, to be used for preparing a pharmaceutical or vaccine against cancer or virus infections.

25 9. A process for induction of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, in mammalian cells, **characterized** in that:

a) the cells are treated with agents that inhibit substances that take place in the cellular peptide processing in mammalian cells e.g. TAP-inhibiting or proteasome inhibiting agents, such as ICP 47, antisense nucleotides or ribozyme together with a pharmaceutically acceptable adjuvant, or
30

- b) a sequence that codes for such an inhibiting agent is introduced into the DNA of the cell, or
- c) a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding a substance that takes place in the cellular peptide processing in mammalian cells e.g. TAP or proteasome is introduced into the DNA of the cell, such as antisense oligonucleotides or ribozyme destroying RNA, or
- d) the cells are treated with an appropriate ribozyme, such as a ribozyme that combine enzymatic processes with the specificity of antisense base pairing, and
- e) when non-mammalian cells are used, such as cells that lack TAP and/or proteasome function and to which human MHC class I molecules have been transfected, e.g. insect cells, transfection thereof with human MHC class I molecules and
- f) the cells may be irradiated with an appropriate dose with e.g. γ -irradiation from e.g. Cs^{137} .

10. A kit, for use in a process for induction of antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, in cells, **characterized** in that it comprises an active dose of a substance that induces antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, such as an inhibitor of TAP or of proteasome or a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding proteasome or TAP e.g. antisense nucleotides or ribozyme, possibly also comprising appropriate adjuvants, such as e.g. cytokines and genes for costimulatory molecules, such as B7, gold beads and liposomes.

11. A pharmaceutical composition or a vaccine comprising a pharmaceutically effective dose of a substance that induces antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, such as an inhibitor of TAP or of proteasome or a gene encoding a proteasome or a TAP inhibitor or a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding proteasome or TAP e.g. antisense nucleotides or ribozyme to-

gether with a pharmaceutically acceptable adjuvant, e.g. cytokines and costimulatory molecules.

12. A process for treatment, prevention and diagnosis of cancer and virus infections, **characterized** in that:

- a) cells taken out of the body of a human being are treated with inhibitors of cellular peptide processing, e.g. TAP-inhibitors, and are readministered to the body possibly together with a pharmaceutically acceptable adjuvant, or
- b) cells that express antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, are administered to the body possibly together with a pharmaceutically acceptable adjuvant, or
- c) autologous T-cells are stimulated in vitro against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, and are administered to the body, or
- d) inhibitors of cellular peptide processing for MHC class I presentation are administered to the body, such as TAP-inhibitors, together with a pharmaceutically acceptable adjuvant, or
- e) antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, are administered to the body, e.g. a peptide or MHC class I complexes or a part thereof, or
- f) a T-cell receptor or a part thereof directed against antigens or epitopes associated with impaired cellular peptide processing, especially MHC class I dependent, is administered to the body.

% Specific Lysis





Figure 1

Effector:Target Ratio

Figure 2



Effector:Target Ratio

[illegible]

Figure 3





Figure 4







Figure 6







Figure 7

% Mice with Tumors



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to Provisional and PCT International Applications)	ATTORNEY'S DOCKET NUMBER
--	---------------------------------

As a below named inventor, I hereby declare that:
 My residence, post office address and citizenship are as stated below next to my name;
 I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH IMPAIRED CELLULAR PEPTIDE PROCESSING, E.G. EXPRESSED ON RMA-S CELLS TRANSECTED WITH A B7-1 GENE

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application
 Number _____
 on _____
 and was amended
 on _____ (if applicable).

☒ was filed as PCT international application
 Number PCT/SE97/02094
 on December 12, 1997
 and was amended under PCT Article 19
 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
Sweden	9604581-0	December 12, 1996	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

(Application Number) _____	(Filing Date) _____
(Application Number) _____	(Filing Date) _____

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED)
 (Includes Reference to Provisional and PCT International Applications)

ATTORNEY'S DOCKET NO.

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations § 1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:

U.S. APPLICATIONS		STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)		

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	George A. Hovanec, Jr.	28,223	Peter K. Skiff	31,917
Peter H. Smolka	15,913	James A. LaBarre	28,632	Richard J. McGrath	29,195
Robert S. Swecker	19,885	E. Joseph Gess	28,510	Matthew L. Schneider	32,814
Platon N. Mandros	22,124	R. Danny Huntington	27,903	Michael G. Savage	32,596
Benson S. Duffett, Jr.	22,030	Eric H. Weisblat	30,505	Gerald F. Swias	30,113
Norman H. Stepao	22,716	James W. Peterson	26,057	Michael J. Ure	33,089
Ronald L. Grudziecki	24,970	Teresa Stunek Rea	30,427	Charles F. Wieland III	33,096
Frederick G. Michaud, Jr.	26,003	Robert E. Krebs	25,885	Bruce T. Wieder	33,815
Alan E. Kopecki	25,813	William C. Rowland	30,888	Todd R. Walters	34,040
Regis E. Shiner	26,999	T. Gene Dillahunty	25,423	Ronni S. Jillions	31,979
Samuel C. Miller, III	27,360	Patrick C. Keane	32,858	Harold R. Brown III	36,341
Ralph L. Freeland, Jr.	16,110	Bruce J. Boggs, Jr.	32,344	Allen R. Baum	36,086
Robert G. Mukai	28,531	William H. Benz	25,952	Steven M. duBois	35,023

and:

Address all correspondence to:

Ronald L. Grudziecki, Esq.
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
 P.O. Box 1404
 Alexandria, Virginia 22313-1404

Address all telephone calls to: _____ at (919) 941-9240.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)		ATTORNEY'S DOCKET NO.
1-00 FULL NAME OF SOLE OR FIRST INVENTOR Elisabeth Wolpert		SIGNATURE <i>[Signature]</i> DATE July 12, 1998
RESIDENCE Stockholm, Sweden SEX		CITIZENSHIP Swedish
POST OFFICE ADDRESS Dalagatan 25, S-113 24 Stockholm, Sweden		
2-00 FULL NAME OF SECOND JOINT INVENTOR, IF ANY Klas Kärre		SIGNATURE <i>[Signature]</i> DATE July 12, 1998
RESIDENCE Nacka, Sweden SEX		CITIZENSHIP Swedish
POST OFFICE ADDRESS Sten Stures Väg 97, S-131 47 Nacka, Sweden		
3-00 FULL NAME OF THIRD JOINT INVENTOR, IF ANY Max Pettersson		SIGNATURE <i>[Signature]</i> DATE July 12, 1998
RESIDENCE Stockholm, Sweden SEX		CITIZENSHIP Swedish
POST OFFICE ADDRESS Kungstengsgatan 31, 5tr. S-113 57 Stockholm, Sweden		
4-00 FULL NAME OF FOURTH JOINT INVENTOR, IF ANY Johan Sandberg		SIGNATURE <i>[Signature]</i> DATE July 12, 1998
RESIDENCE Solna, Sweden SEX		CITIZENSHIP Swedish
POST OFFICE ADDRESS Parkvägen 19, S-171 38 Solna, Sweden		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		